Source:http://linkedlifedata.com/resource/pubmed/id/10233049
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5 Pt 2
|
| pubmed:dateCreated |
1999-6-3
|
| pubmed:abstractText |
Glucagon-like peptide-1-(7-36) amide (GLP-1) is an incretin hormone of the enteroinsular axis. Recent experimental evidence in animals and healthy subjects suggests that GLP-1 has a role in controlling appetite and energy intake in humans. We have therefore examined in a double-blind, placebo-controlled, crossover study in 12 patients with diabetes type 2 the effect of intravenously infused GLP-1 on appetite sensations and energy intake. On 2 days, either saline or GLP-1 (1.5 pmol. kg-1. min-1) was given throughout the experiment. Visual analog scales were used to assess appetite sensations; furthermore, food and fluid intake of a test meal were recorded, and blood was sampled for analysis of plasma glucose and hormone levels. GLP-1 infusion enhanced satiety and fullness compared with placebo (P = 0.028 for fullness and P = 0.026 for hunger feelings). Energy intake was reduced by 27% by GLP-1 (P = 0.034) compared with saline. The results demonstrate a marked effect of GLP-1 on appetite by showing enhanced satiety and reduced energy intake in patients with diabetes type 2.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Blood Glucose,
http://linkedlifedata.com/resource/pubmed/chemical/Glucagon,
http://linkedlifedata.com/resource/pubmed/chemical/Glucagon-Like Peptide 1,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin,
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Precursors
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0002-9513
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
276
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
R1541-4
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:10233049-Appetite,
pubmed-meshheading:10233049-Blood Glucose,
pubmed-meshheading:10233049-Brain Chemistry,
pubmed-meshheading:10233049-Cross-Over Studies,
pubmed-meshheading:10233049-Diabetes Mellitus, Type 2,
pubmed-meshheading:10233049-Double-Blind Method,
pubmed-meshheading:10233049-Eating,
pubmed-meshheading:10233049-Glucagon,
pubmed-meshheading:10233049-Glucagon-Like Peptide 1,
pubmed-meshheading:10233049-Humans,
pubmed-meshheading:10233049-Hyperglycemia,
pubmed-meshheading:10233049-Infusions, Intravenous,
pubmed-meshheading:10233049-Insulin,
pubmed-meshheading:10233049-Male,
pubmed-meshheading:10233049-Middle Aged,
pubmed-meshheading:10233049-Obesity,
pubmed-meshheading:10233049-Peptide Fragments,
pubmed-meshheading:10233049-Protein Precursors,
pubmed-meshheading:10233049-Satiation
|
| pubmed:year |
1999
|
| pubmed:articleTitle |
Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2.
|
| pubmed:affiliation |
Department of Internal Medicine, Kantonsspital, CH-5000 Aarau, Switzerland.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Controlled Clinical Trial
|